MRI volumetry and histopathological analysis demonstrated significant tumor regression in the S-biAb/dEGCG@NP cohort (Fig. 17c), with concomitant survival benefit (Fig. 17d), validating MMP-2-sensitive nanoparticle efficacy against GBM. Here, MMP2 is linked to glioblastoma.